Skip to content

Drug interactions

Crizotinib + Zanubrutinib

Severity: Moderate

Crizotinib and Zanubrutinib: moderate interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Crizotinib, a moderate CYP3A inhibitor, can increase zanubrutinib exposure. This may increase the risk of hematologic toxicity, infection and bleeding.

What this interaction means in plain words

Crizotinib and Zanubrutinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.

Crizotinib belongs to Oncology; Zanubrutinib belongs to Oncology.

Evidence level: High

Why it happens

Crizotinib inhibits CYP3A4, reducing the first-pass and systemic metabolism of zanubrutinib.

What to do

Reduce the zanubrutinib dose to 80 mg twice daily during coadministration, per labeling. Monitor blood counts and for bleeding, and resume the usual dose after crizotinib is stopped.

What to ask your pharmacist

  • Should I take them at different times of day?
  • Does the dose of either medicine need to change?
  • Is there anything I should avoid, such as alcohol or certain foods, while on both?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Crizotinib and Zanubrutinib, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 7 days on the web. No card needed.

Frequently asked questions

Can I take Crizotinib with Zanubrutinib?

MediHelp rates the interaction as moderate. Crizotinib and Zanubrutinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Crizotinib, a moderate CYP3A inhibitor, can increase zanubrutinib exposure. This may increase the risk of hematologic toxicity, infection and bleeding.

How serious is the interaction between Crizotinib and Zanubrutinib?

MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Reduce the zanubrutinib dose to 80 mg twice daily during coadministration, per labeling. Monitor blood counts and for bleeding, and resume the usual dose after crizotinib is stopped.

What other medicines interact with Crizotinib?

MediHelp also lists interactions of Crizotinib with, for example, Flibanserin, Lomitapide, Lonafarnib. The full list is on the Crizotinib page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in